Within 90 days prior to registration: Complete dental exam; complete elimination of dental and periodontal pathology including crowns on teeth susceptible to fracture, extraction of non-restorable or periodontally uncorrectable teeth; creation of an oral environment that the patient can efficiently maintain in a high state of health; and oral hygiene instruction to maintain excellent oral health
Dental braces or prosthesis that interferes with tumor imaging
Planned vacation or dental work during the study phase
Other concurrent severe and/or uncontrolled medical conditions including need for urgent dentoalveolar surgery as indicated by preventative dental exam
No known/planned active dental or jaw condition which requires oral surgery, including tooth extraction
No known non-healed dental/oral surgery, including tooth extraction
Patients have planned invasive dental procedures during the course of the study
Dental braces or prosthesis that interferes with volumetric analysis of the neurofibroma(s)
Signs and symptoms of infection within 2 weeks of first study treatment; receipt of therapeutic oral or IV antibiotics within 2 weeks of first study treatment; subjects receiving routine antibiotic prophylaxis (for dental extractions/procedures) are eligible
Patients have prior history or current evidence of osteonecrosis or osteomyelitis of the jaw, evidence of untreated local gum or oral infection, or non-healed dental or oral surgery
Patients with active dental or jaw conditions which require oral surgery/dental procedures, including tooth extraction for the course of the study
Dental braces or prosthesis that interferes with MR imaging
Dental evaluation with management prior to start of radiation
Signs and symptoms of active dental disease
Active dental or jaw condition that requires oral surgery, including tooth extraction
Non-healed dental/oral surgery, including tooth extraction
Planned invasive dental procedures during the course of study
Pre-existing conditions\r\n* Disorders associated with abnormal bone metabolism\r\n* Hypocalcemia that is not corrected with oral calcium supplementation\r\n* Vitamin D < 20 mg/mL\r\n* Pagetâ€™s disease\r\n* Prior history or current evidence of osteonecrosis of the jaw\r\n* Any dental or oral condition likely to result in disruption of mucosal integrity during denosumab therapy including: active dental or jaw condition requiring oral surgery or tooth extraction; non-healed dental or oral surgery or planned invasive dental procedures during the anticipated course of study therapy\r\n* Unstable systemic disease, excluding osteosarcoma, such as unstable proximal renal tubule dysfunction (Fanconi syndrome) or congestive heart failure
Patients have active dental or jaw condition which requires oral surgery, including tooth extraction
Patients have non healed dental/oral surgery, including tooth extraction
Patients planned invasive dental procedures
Active dental infection
Active dental or jaw condition which requires oral surgery
Planned invasive dental procedure for the course of the study
Non-healed dental or oral surgery
Allergy to implant materials or dental glue.
Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, or with the following:
Active dental or jaw condition which requires oral surgery
Non-healed dental/oral surgery
Planned invasive dental procedures for the course of the study.
Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures
Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)
Active dental or jaw condition which requires oral surgery
Non-healed dental/oral surgery
Planned invasive dental procedure for the course of the study
Impending invasive dental procedure that would be expected to occur during study participation (through day 360)
Infection requiring receipt of therapeutic oral or IV anti-microbials within 2 weeks of first study treatment; patients receiving routine anti-microbial prophylaxis (for dental extractions/procedures) are eligible
Active dental or jaw condition which requires oral surgery, including tooth extraction
Non-healed dental/oral surgery, including tooth extraction
Planned invasive dental procedures
Has incompletely healed sites of dental extractions
Participants must have a dental examination within 6 months of enrolling in the study
Prior history or current evidence of osteonecrosis or osteomyelitis of the jaw, evidence of untreated local gum or oral infection, or non-healed dental or oral surgery
Active dental or jaw conditions which require oral surgery/dental procedures, including tooth extraction within 6 months of the study
Other risk factors for the development of osteonecrosis of the jaw (ONJ) including poor oral hygiene, use of a dental appliance, immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, or gingival infections
Receipt of therapeutic oral or IV antibiotics within 2 weeks of first study treatment; subjects receiving routine antibiotic prophylaxis (for dental extractions/procedures) are eligible
Patients with ongoing symptomatic dental infections
Patients with excessive dental restorations and amalgam
Medical condition which requires pre-medication prior to dental visits/procedures
5 or more decayed, untreated dental sites (cavities)
Plan to receive dental treatment during the study dates
